GlassScriptPhysician profile
Jennifer Denney
NPI 1689389199
$1,991.97
in general payments reported to CMS, 2019-2025
27 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $488 · 2024: $1,009 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $237.08 | 2023-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $222.04 | 2023-2025 | Tremfya, Stelara |
| Aurinia Pharma U.S., INC. | $174.82 | 2023-2025 | Lupkynis |
| Abbvie INC. | $156.75 | 2023-2025 | |
| Madrigal Pharmaceuticals | $135.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $112.65 | 2023-2024 | Dificid, Pifeltro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.98 | 2023-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $98.83 | 2023-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $91.28 | 2023-2024 | Dupixent |
| Evoke Pharma, INC. | $77.20 | 2023-2024 | Gimoti |
| Ucb, INC. | $67.25 | 2024-2025 | Bimzelx, Cimzia |
| Phathom Pharmaceuticals, INC. | $65.87 | 2024-2025 | Voquezna |
| Medtronic, INC. | $58.88 | 2024-2025 | Interstim |
| Organon LLC | $47.28 | 2023-2024 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $47.11 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $45.04 | 2023-2024 | Ocaliva |
| Pfizer INC. | $36.24 | 2024 | |
| Ardelyx, INC. | $35.19 | 2023-2025 | Ibsrela |
| Amgen INC. | $27.11 | 2023 | Amjevita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.15 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.65 | 2023 | Givlaari |
| Scilex Pharmaceuticals INC. | $20.65 | 2024 | |
| Braintree Laboratories, INC. | $18.93 | 2023 | Sutab |
| Genzyme Corporation | $17.97 | 2024 | |
| Ironwood Pharmaceuticals, INC | $17.30 | 2024 | |
| Chiesi USA, INC. | $17.18 | 2025 | Cleviprex |
| Fresenius Kabi USA, LLC | $15.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Denney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.